Manufacturing Optimization for Filovirus Monoclonal Antibodies
As a part of BARDA’s commitment to develop therapeutic countermeasures against filovirus disease, BARDA is interested in advancing manufacturing development for a monoclonal antibody (mAb) cocktail composed of two mAbs. These medical countermeasures (MCM) can be deployed in the event of a filovirus outbreak and are a crucial component to the United States Government’s (USG’s) outbreak response plan. BARDA is seeking to augment the USG’s response capabilities through these awards, with therapeutics targeting filovirus disease caused by Ebola virus (EBOV), Marburg virus (MARV), or Sudan virus (SUDV).
Applying Data-Driven AI Models for High-yield Manufacturing of 1C3 and 1C11
Project Details
Member Organization: Asimov, Inc.
Award Date: 07/14/2025
Award Ceiling (Base Period): $1,769,235
Project Duration: 15 months (Base Period)
Solicitation Number: RPP-24-07-mAbs
Developing High Productivity Chinese Hamster Ovary Cell Lines for Manufacturing Filovirus Monoclonal Antibodies for Therapeutic or Prophylactic Use
Project Details
Member Organization: CHO Plus, Inc.
Award Date: 07/28/2025
Award Ceiling (Base Period): $1,609,720
Project Duration: 15 months (Base Period)
Solicitation Number: RPP-24-07-mAbs
